Marilina Neokleous

Ms. Marilina Neokleous


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSotiris Kyriakou
Sotiris Kyriakou
AKArgyris Kyriakou
Argyris Kyriakou
MNMarilina Neokleous
Marilina Neokleous
EBEREN OZAN BAKIR
EREN OZAN BAKIR
PAPetros Agathangelou
Petros Agathangelou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Percutaneous coronary intervention (PCI) treats focal coronary obstruction by compressing plaque, injuring the vessel wall and placing a metallic or bioresorbable scaffold. Most treated segments heal, but a small minority enter a prolonged, excessive or unstable repair state that contributes to in-stent restenosis (ISR), in-stent neoatherosclerosis and stent thrombosis (ST). Human evidence is strongest for delayed healing, uncovered struts, macrophage-rich neoatherosclerosis and hypersensitivity-associated late thrombosis, whereas routine immune biomarker-guided care remains unsupported. The narrowed lumen is only the visible endpoint; beneath it sits vascular repair shaped by de-vice-material exposure, local haemodynamics and host immunity. Endothelial denuda-tion and platelet activation initiate fibrin deposition, complement signalling and dam-age-associated molecular-pattern (DAMP) release. Neutrophils, monocytes and macro-phages dominate early, followed by lymphocytes and vascular smooth muscle cells that remodel the repair compartment. Drug-eluting stents (DES) have markedly reduced early neointimal hyperplasia, yet selected late failures still involve delayed endothelial recovery, chronic peristrut inflammation, hypersensitivity and neoatherosclerotic transformation. Immune biology is useful at the bedside only when interpreted with procedural context, device design and patient phenotype. Imaging-defined endpoints and paired immune phenotyping are therefore needed to guide treatment by mechanism instead of angiography or isolated biomarkers.

9 July 2026 in Immuno
Verified
Journal Article
Open access
PDF file
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
AKArgyris Kyriakou
Argyris Kyriakou
MNMarilina Neokleous
Marilina Neokleous
EBEREN OZAN BAKIR
EREN OZAN BAKIR
PAPetros Agathangelou
Petros Agathangelou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Percutaneous coronary intervention (PCI) treats focal coronary obstruction by compressing plaque, injuring the vessel wall, and placing a metallic or bioresorbable scaffold. Most treated segments heal, but a small minority enter a prolonged, excessive, or unstable repair state that contributes to in-stent restenosis (ISR), in-stent neoatherosclerosis, and stent thrombosis (ST). Human evidence is strongest for delayed healing, uncovered struts, macrophage-rich neoatherosclerosis, and hypersensitivity-associated late thrombosis, whereas routine immune biomarker-guided care remains unsupported. The practical question addressed here is therefore not whether inflammation participates, which is established, but which immune signals, read together with intravascular imaging, could realistically change post-PCI management. The narrowed lumen is only the visible endpoint; beneath it sits vascular repair shaped by device-material exposure, local haemodynamics, and host immunity. Endothelial denudation and platelet activation initiate fibrin deposition, complement signalling, and release of damage-associated molecular patterns (DAMPs). Neutrophils, monocytes, and macrophages dominate early, followed by lymphocytes and vascular smooth muscle cells that remodel the repair compartment. Drug-eluting stents (DES) have markedly reduced early neointimal hyperplasia, yet selected late failures still involve delayed endothelial recovery, chronic peristrut inflammation, hypersensitivity, and neoatherosclerotic transformation. Immune biology is useful at the bedside only when interpreted with procedural context, device design, and patient phenotype. Imaging-defined endpoints and paired immune phenotyping are therefore needed to guide treatment by mechanism instead of angiography or isolated biomarkers.

26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
KSKlitia Socratous
Klitia Socratous
SKSotiris Kyriakou
Sotiris Kyriakou
KLKonstantinos Lampropoulos
Konstantinos Lampropoulos
PGPanos Georghiou
Panos Georghiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Aortitis—inflammation of the aortic wall—presents at the interface of vasculitis, infection, structural aortic disease, and cardiovascular risk. It may occur in giant cell arteritis (GCA), Takayasu arteritis, IgG4-related disease, drug-induced injury, infection, or as an isolated finding after aortic surgery. Modern imaging detects aortic inflammation more frequently, but the main challenge is classification rather than detection: determining whether disease is infectious or immune-mediated, active or dominated by fixed structural damage, systemic or isolated, and whether the dominant threat is aneurysm, dissection, undertreated infection, or avoidable immunosuppression. This review considers aortitis as a high-risk vascular syndrome requiring aetiology-first classification rather than descriptive labelling. Before escalating immunosuppression, infection must be actively excluded and inflammatory activity distinguished from fixed vascular damage. Treatment should be individualised according to phenotype, age, vascular territory, comorbidity, and toxicity risk, with surveillance continuing even after symptoms and inflammatory markers improve. Optimal care depends on multidisciplinary assessment integrating rheumatology, infectious diseases, vascular surgery, radiology, and cardiology expertise. Progress will require standardised imaging definitions, registries linking inflammatory control with structural vascular outcomes, and validation of artificial intelligence (AI) tools before clinical adoption.